CERTNMSHealthcare·Health Information Services#15 in industry

Certara, Inc.

Reports in 14d· 2026-05-11

-35.1% · 90d

$6.29

-0.04 (-0.55%)

News

(2)

April 2026

Apr 22, 20265 days ago8-KHealthcare

Certara Sells Regulatory Writing Business for $135 Million

CERTCertara, Inc.

# 🧾 What This Document Is This is an 8-K filing, which companies use to announce major, unexpected events to investors. This specific filing contains a press release (Exhibit 99.1) announcing that Certara is selling a part of its business. The filing signals a significant strategic shift for the co

Read summaryView on SEC EDGAR

Apr 3, 20263 weeks agoDEF 14AHealthcare

Certara, Inc. — DEF 14A Filing

CERTCertara, Inc.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Certara, Inc.'s 2026 Annual Meeting of Stockholders. Think of it as the official "meeting packet" that gives shareholders all the info they need to vote on key company decisions. It explains what will be voted on, who

Read summaryView on SEC EDGAR

Key Data

Market Cap$963.6M

Open$6.27

Prev Close$6.32

Day Range$6.26 – $6.44

52W Range$5.19 – $14.39

Volume968,557

P/E (TTM)—

EPS$-0.01

Dividend Yield—

Beta1.62

Profit Margin-0.38%

Revenue Growth3.30%

Price Target$8.71(+38.6%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Buy13 analysts

Buy 5Hold 8Sell 0

About

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Healthcare · Health Information Services

1,515 employees

www.certara.com